延长来那度胺维持治疗可加深多发性骨髓瘤的缓解深度
该回顾性分析纳入139例在新诊断多发性骨髓瘤维持治疗中接受来那度胺、且治疗期间以灵敏度至少10⁻⁴的多参数流式细胞术或二代测序监测MRD的真实世界患者。来那度胺维持与缓解深度增加相关,38.1%的患者在维持期间达到最大缓解,诱导后MRD阳性的患者中34.3%在维持期间转为MRD阴性并最终获得改善的PFS。连续MRD评估可识别MRD水平逐步下降且PFS更优的患者。
要点
- 来那度胺维持期间38.1%的患者达到最大缓解。
- 诱导后MRD阳性者中34.3%在维持期间转为MRD阴性并PFS改善。
- 连续MRD评估可识别MRD逐步下降且PFS更优的患者。
核心结论
- 来那度胺维持治疗不仅维持、还可加深疾病缓解深度并带来PFS获益。
- 维持期间MRD监测可识别预后更好的患者,可能有助于其临床管理。
研究设计与样本
- 回顾性分析139例在新诊断多发性骨髓瘤维持治疗中接受来那度胺的真实世界临床实践患者,其MRD水平在治疗期间以灵敏度至少10⁻⁴的多参数流式细胞术或二代测序监测。
主要发现
- 来那度胺维持与疾病缓解深度增加相关,38.1%的患者在维持期间达到最大缓解。
- 诱导治疗后MRD阳性的患者中,34.3%在维持期间达到MRD阴性状态并最终获得改善的PFS。
- 连续MRD评估识别出MRD水平逐步下降的患者,其PFS结局优于未显示MRD下降模式的患者。
临床怎么用
- 来那度胺维持治疗不仅维持、还可加深疾病缓解深度并带来PFS获益。
- 维持期间MRD监测可识别预后更好的患者,可能有助于其临床管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lenalidomide is an immunomodulatory drug approved for maintenance treatment in newly diagnosed multiple myeloma, and it has been shown to improve progression-free survival (PFS) and, in several studies, overall survival. Nevertheless, the impact of prolonged treatment with lenalidomide on the kinetics of minimal residual disease (MRD) and its prognostic impact have not been studied in depth. To obtain better knowledge in this regard, we retrospectively analyzed 139 patients who received lenalidomide maintenance in real-world clinical practice and whose MRD levels were observed during the treatment period by multiparametric flow cytometry or next-generation sequencing with a sensitivity of at least 10-4. Lenalidomide maintenance correlated with an increased depth of the disease response, with 38.1% of patients achieving maximal response during maintenance. Moreover, 34.3% of patients who were MRD positive after induction treatment achieved MRD-negative status during maintenance and ultimately had improved PFS. Sequential MRD assessments identified patients with progressively decreasing MRD levels who also had better PFS outcomes, compared with patients not showing a decreasing pattern of MRD. These results support the role of maintenance therapy, not only to sustain, but also to increase the depth of disease response with a PFS benefit. In addition, MRD monitoring during maintenance identifies patients with better prognosis and may help in their clinical management.
引用
- Alonso R, Cedena MT, Wong S, et al. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood Adv. 2020. PMID: 32433744. doi:10.1182/bloodadvances.2020001508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。